Yu AM - Search Results

1

Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo.

Zhang QY, Ho PY, Tu MJ, Jilek JL, Chen QX, Zeng S, Yu AM. Zhang QY, et al. Among authors: yu am. Int J Pharm. 2018 Aug 25;547(1-2):537-544. doi: 10.1016/j.ijpharm.2018.06.026. Epub 2018 Jun 9. Int J Pharm. 2018. PMID: 29894758 Free PMC article.

2

An overview of ABC and SLC drug transporter gene regulation.

Chen QX, Hu HH, Zhou Q, Yu AM, Zeng S. Chen QX, et al. Among authors: yu am. Curr Drug Metab. 2013 Feb;14(2):253-64. Curr Drug Metab. 2013. PMID: 23116109 Review.

3

A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications.

Chen QX, Wang WP, Zeng S, Urayama S, Yu AM. Chen QX, et al. Among authors: yu am. Nucleic Acids Res. 2015 Apr 20;43(7):3857-69. doi: 10.1093/nar/gkv228. Epub 2015 Mar 23. Nucleic Acids Res. 2015. PMID: 25800741 Free PMC article.

4

Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Li MM, et al. Among authors: yu am. Drug Metab Dispos. 2015 Jul;43(7):1129-36. doi: 10.1124/dmd.115.064493. Epub 2015 May 1. Drug Metab Dispos. 2015. PMID: 25934574 Free PMC article.

5

Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.

Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, White RD, Lam KS, Yu AM. Wang WP, et al. Among authors: yu am. J Pharmacol Exp Ther. 2015 Aug;354(2):131-41. doi: 10.1124/jpet.115.225631. Epub 2015 May 28. J Pharmacol Exp Ther. 2015. PMID: 26022002 Free PMC article.

6

Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.

Zhao Y, Tu MJ, Yu YF, Wang WP, Chen QX, Qiu JX, Yu AX, Yu AM. Zhao Y, et al. Among authors: yu ax, yu am, yu yf. Biochem Pharmacol. 2015 Dec 15;98(4):602-13. doi: 10.1016/j.bcp.2015.10.015. Epub 2015 Oct 27. Biochem Pharmacol. 2015. PMID: 26518752 Free PMC article.

7

MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. Yu AM, et al. Drug Metab Dispos. 2016 Mar;44(3):308-19. doi: 10.1124/dmd.115.067470. Epub 2015 Nov 13. Drug Metab Dispos. 2016. PMID: 26566807 Free PMC article. Review.

8

Bioengineering of noncoding RNAs for research agents and therapeutics.

Ho PY, Yu AM. Ho PY, et al. Among authors: yu am. Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):186-97. doi: 10.1002/wrna.1324. Epub 2016 Jan 13. Wiley Interdiscip Rev RNA. 2016. PMID: 26763749 Free PMC article. Review.

9

Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.

Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. Zhao Y, et al. Among authors: yu ax, yu am. Sci Rep. 2016 May 24;6:26611. doi: 10.1038/srep26611. Sci Rep. 2016. PMID: 27216562 Free PMC article.

10

MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis.

Tu MJ, Pan YZ, Qiu JX, Kim EJ, Yu AM. Tu MJ, et al. Among authors: yu am. Oncotarget. 2016 Jul 19;7(29):45547-45561. doi: 10.18632/oncotarget.9999. Oncotarget. 2016. PMID: 27322206 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters